CardioFocus, Inc., developer of the clever HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), has featured before on our pages, most recently in June when a study published in the journal Heart Rhythm demonstrated high procedural success and durable pulmonary vein isolation. The company has now announced that its technology will be highlighted in two presentations during the European Society of Cardiology (ESC) Congress 2012, in Munich, Germany, August 25-29.
In addition, the technology will be featured at an evening academic symposium, where cardiology thought leaders will discuss their experiences with the HeartLight system.
The HeartLight EAS is the first catheter ablation technology to incorporate an endoscope for direct visualisation of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the area surrounding the pulmonary veins irrespective of the individual patient anatomy. It also utilises laser energy for what the company claims is more efficient and precise ablation treatment.
Stephen Sagon, President and CEO of CardioFocus, said, “The findings presented at this meeting examine the use of our technology in the treatment of AF, spanning topics regarding pulmonary vein isolation, long-term treatment durability, and clinical outcomes with HeartLight directly compared to other systems. These data derive from the experiences of prominent electrophysiology experts across the world, and we expect that the results will continue to substantiate the clinical utility, as well as encourage expanded commercial use of the system.”
The HeartLight system will be discussed during the “Catheter ablation of atrial fibrillation: New Tools” session on Sunday, August 26 at 2 p.m. in the following presentations:
P1490: Pulmonary vein isolation for paroxysmal atrial fibrillation with the laser balloon
Authors: L Sediva, J Petru, J Skoda, M Janotka, M Chovanec and P Neuzil of Na Homolce Hospital in Prague, Czech Republic
Presentation will review chronic outcomes of HeartLight EAS cases performed during the preceding three years at Na Homolce Hospital
P1493: Laser or Cryo? Prospective comparison of balloon based PVI technologies
Authors: S Bordignon, KRJ Chun, M Gunawardene, M Kulikoglu, V Urban, B Schulte-Hahn, B Nowak and B Schmidt of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
The HeartLight Symposium will take place Monday, August 27 at 6:30 p.m. at the Bayerischer Hof Hotel, and will be chaired by Prof. Thorsten Lewalter, MD, of the Isar Heart Center in Munich and Prof. Petr Neuzil, MD, of Na Homolce Hospital. It will feature multicentre data on the durability of pulmonary vein isolation with the HeartLight system, a discussion of outcomes with different balloon catheter technologies, as well as presentations evaluating safety and efficacy in AF ablation.
The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe and in Australia. The device is not FDA approved and for investigational use only in the U.S.
Source: Cardiofocus Inc., PR Newswire